Its associated monoclonal antibodies, anti-CD52, including alemtuzumab and analogues, are intended for treatment of multiple sclerosis and B cell chronic lymphocytic leukemia [34], with its specific expression patterns being observed in the inflammatory meta program. This evidence concerns the gene CD52 and multiple sclerosis.